cell

German pharmaceutical firm Boehringer Ingelheim has received approval for olmutinib (BI 1482694 / HM61713) in South Korea, to treat patients suffering from locally advanced or metastatic, epidermal growth factor receptor (EGFR), T790M, mutation-positive, non-small cell lung cancer (NSCLC).

The treatment can work on patients who had previously been treated with an EGFR tyrosine kinase inhibitor (TKI).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Hanmi Pharmaceutical will be responsible for distributing the compound in South Korea, under the name olmutinib.

The South Korean approval is based on the successful results of the Phase I/II HM-EMSI-101 (NCT01588145) clinical trial.

Sungkyunkwan University School of Medicine Seoul South Korea Samsung Medical Centre innovative cancer medicine institute (ICMI) director Keunchil Park said: "The approval of olmutinib is a great step forward for lung cancer patients in South Korea.

"This is an exciting and much needed new treatment option for the majority of EGFR mutation-positive lung cancer patients whose disease has become resistant to first-line TKI therapy, which can be a devastating development."

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData
"This is an exciting and much needed new treatment option for the majority of EGFR mutation-positive lung cancer patients whose disease has become resistant to first-line TKI therapy."

Olmutinib (BI 1482694 / HM61713) is a third-generation, oral, EGFR mutation-specific TKI.

The primary Phase II trial ELUXA 1 (HM-EMSI-202 [NCT02485652]) is under way, thereby enrolling EGFR T790M, mutation-positive lung cancer patients who have become resistant to TKI treatment for the olmutinib treatment.

Last year, Boehringer signed an exclusive license agreement with Hanmi to gain exclusive rights for the product across the globe, except in South Korea and Hong Kong.

ZAI Lab has secured exclusive rights for the product within China, including Hong Kong and Macau.

Image: Micrographs of positive non-small cell lung cancer. Photo: courtesy of Nephron / Wikipedia.

Pharmaceutical Technology Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now